Table 1.
Parenteral rotavirus vaccines in development.
| Vaccine | Characteristic | Developer | Status |
|---|---|---|---|
| Non-replicating RV vaccine (NRRV) | |||
| Monovalent | VP8 Fragment genotype [P8] | NIH – PATH | Phase 1: Safe in infants Phase 2: Immunogenic; protects against shedding of Rotarix |
| Trivalent | VP8: 3 Fragments [P8] [P4] [P6] | PATH – NIH | Phase 2: Ongoing |
| Inactivated RV vaccine (IRV) | |||
| By Heat | Strain CDC-9 (G1, P [8]) | CDC | Immunogenic: mice/monkeys/piglets Protective: piglets
|
| By Formaldehyde | Strain RV ZTR-68 (G1, P [8]) | Kunming Institute of Medical Biology, China | Immunogenic: mice Protective: mice |
| Expressed proteins | |||
| VP6 | VP6 combined with norovirus VLP† | Cincinnati Children’s Hospital; Univ. of Tampere, Finland | Immunogenic: mice Protective: mice |
| VLPa in insect cells | VLP containing VP2/6/7 or VP2/4/6/7 |
Baylor College of Medicine | Immunogenic: mice Protective: mice, rabbits |
| VLPa in plants | Medicago/Mitsubishi Tanabe Pharma, Japan | Immunogenic: mice Protective: mice |
|
This table is adapted from Kirkwood et al. [8].
a
Virus Like Particles (VLP).